Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 15/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584477 | 0.91 | HTR1A (0.48) | CCR1HTR1ASLC6A4DRD4CYP1A2 | |
| SCHEMBL14571526 | 0.91 | HTR1A (0.48) | CCR1HTR1ASLC6A4DRD4CYP1A2 | |
| SCHEMBL5584405 | 0.90 | HTR1A (0.52) | CCR1HTR1ASLC6A4DRD4CYP1A2 | |
| Hydrochloric Acid SCHEMBL5584890 | 0.90 | HTR1A (0.48) | CCR1HTR1ASLC6A4DRD4CYP1A2 | |
| SCHEMBL14571538 | 0.89 | CCR1 (0.42) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL14571590 | 0.89 | DRD4 (0.47) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL5584776 | 0.89 | HTR1A (0.48) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL14571637 | 0.89 | HTR1A (0.52) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL5584460 | 0.89 | HTR1A (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL14571549 | 0.88 | KCNH2 (0.47) | CCR1HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | CCR1 2772/4885HTR1A 1/4885SLC6A4 10/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | CCR1 2772/4885HTR1A 1/4885SLC6A4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.